Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cardiol Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $2.72 Mil. Cardiol Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $5.17 Mil. Cardiol Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $17.12 Mil. Therefore, Cardiol Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.14.
Cardiol Therapeutics Scaled Net Operating Assets Related Terms
Cardiol Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics Scaled Net Operating Assets Chart
CRDL vs ZTS, UTHR: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.14 mean?
Cardiol Therapeutics (CRDL) has a Scaled Net Operating Assets of -0.14 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cardiol Therapeutics and its competitors.
Is Cardiol Therapeutics' Scaled Net Operating Assets too high?
Cardiol Therapeutics' current Scaled Net Operating Assets is -0.14. Overall, Cardiol Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Scaled Net Operating Assets compare to ZTS and UTHR?
Cardiol Therapeutics' Scaled Net Operating Assets of -0.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Scaled Net Operating Assets is -0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (CRDL) has a current Scaled Net Operating Assets of -0.14. The current Scaled Net Operating Assets is -0.14. Cardiol Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Cardiol Therapeutics (CRDL), the current Scaled Net Operating Assets is -0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
34GF Score
Get the complete analysis for CRDL
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDL has been successfully added to your 
